|
|
|
|
|||||
|
|
|
We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Nuvation Bio Inc. stands seventh on our list among the best oncology stocks.
TheFly reported on January 12 that H.C. Wainwright reduced its price target on NUVB to $17 from $18 while maintaining a Buy rating. The firm said the company’s fourth-quarter Ibtrozi sales came in line with expectations.
On the same day, NUVB reported preliminary Q4 2025 net product revenue of approximately $15.7 million for IBTROZI (taletrectinib). The company also highlighted that 216 new patients started treatment with IBTROZI in the fourth quarter and received a $25 million milestone payment from Nippon Kayaku.
Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology patients. Its lead asset, IBTROZI (taletrectinib), targets rare and difficult-to-treat cancers. The company emphasizes precision medicine, pipeline expansion, and improving outcomes for patients with limited therapeutic options in oncology.
While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
| 15 hours | |
| Jan-19 | |
| Jan-15 | |
| Jan-13 | |
| Jan-12 | |
| Jan-12 | |
| Jan-06 | |
| Jan-05 | |
| Dec-19 | |
| Dec-15 | |
| Dec-06 | |
| Dec-04 | |
| Dec-03 | |
| Nov-26 | |
| Nov-20 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite